Curanex Pharmaceuticals Inc (CURX) Peer Comparison
$4.74
$0.20
(4.29%)
As on 03-Sep-2026 16:00EDT
Market cap
$7 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
1.5
Div. Yield
0 %
Edit
| Curanex Pharmaceuticals Inc (CURX) | Lineage, Inc. (LINE) | Viamet Pharmaceuticals Corp (VMET) | MAKO Surgical Corp (MAKO) | Republic Airways Holdings Inc (RJET) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
7 | 9,859 | 1,113 | 893 | 861 |
Revenue ($ Mln) |
-- | 5,371 | 73 | 208 | 1,653 |
Net Profit ($ Mln) |
-10.47 | -169.00 | 36.72 | 52.16 | 48.98 |
Net Margin (%) |
-- | -3.15 | 50.13 | 25.13 | 2.96 |
RoE (%) |
-130.80 | -1.85 | 11.69 | 30.61 | 3.61 |
Price to Earnings |
-- | -- | 28.42 | 17.27 | 12.19 |
Price-To-Book |
1.53 | 1.14 | 2.92 | 5.03 | 0.62 |
Income Statement ($ Mln)
| Curanex Pharmaceuticals Inc (CURX) | Lineage, Inc. (LINE) | Viamet Pharmaceuticals Corp (VMET) | MAKO Surgical Corp (MAKO) | Republic Airways Holdings Inc (RJET) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
0.00 | 5,371.00 | 73.25 | 207.57 | 1,653.28 |
|
Cost of Revenue
|
0.07 | 4,782.00 | 33.19 | 99.94 | 1,215.66 |
|
Gross Profit
|
-- | 826.00 | 13.48 | 75.02 | 466.00 |
|
Operating Expenses
|
10.48 | 319.00 | 11.50 | 23.17 | 269.36 |
|
Operating Profit (EBIT)
|
-10.55 | 270.00 | 28.55 | 84.46 | 168.25 |
|
Other Income
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Profit before Tax
|
-10.47 | -189.00 | 52.29 | 83.59 | 86.32 |
|
Provision for Tax
|
0.00 | 0.00 | 15.57 | 31.44 | 37.34 |
|
Profit after Tax (Net Income)
|
-10.47 | -169.00 | 36.72 | 52.16 | 48.98 |
|
Minority Interest
|
0.00 | 20.00 | 0.00 | 0.00 | 0.00 |
|
Consolidated Profit
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Liabilities ($ Mln)
| Curanex Pharmaceuticals Inc (CURX) | Lineage, Inc. (LINE) | Viamet Pharmaceuticals Corp (VMET) | MAKO Surgical Corp (MAKO) | Republic Airways Holdings Inc (RJET) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
4.79 | 7,893.00 | 394.08 | 190.04 | 1,386.30 |
|
Minority Interest
|
0.00 | 20.00 | 0.00 | 0.00 | 0.00 |
|
Non-Current Liabilities
|
0.18 | 8,436.00 | 340.68 | 55.77 | 1,349.70 |
|
Current Liabilities
|
0.10 | 1,590.00 | 52.51 | 50.34 | 520.40 |
|
Total Liabilities
|
11.58 | 19,185.00 | 418.01 | 208.45 | 3,276.60 |
Assets ($ Mln)
| Curanex Pharmaceuticals Inc (CURX) | Lineage, Inc. (LINE) | Viamet Pharmaceuticals Corp (VMET) | MAKO Surgical Corp (MAKO) | Republic Airways Holdings Inc (RJET) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
0.28 | 17,659.00 | 750.06 | 139.74 | 2,721.30 |
|
Current Assets
|
4.79 | 1,241.00 | 37.20 | 156.41 | 535.10 |
|
Total Assets
|
11.58 | 19,185.00 | 418.01 | 208.45 | 3,276.60 |
|
Total Debt*
|
0.28 | 7,991.00 | 374.55 | 41.69 | 1,194.50 |
|
Net Current Assets
|
0.00 | -349.00 | 0.00 | 0.00 | 14.70 |
Cashflow ($ Mln)
| Curanex Pharmaceuticals Inc (CURX) | Lineage, Inc. (LINE) | Viamet Pharmaceuticals Corp (VMET) | MAKO Surgical Corp (MAKO) | Republic Airways Holdings Inc (RJET) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-10.48 | 943.00 | 16.95 | 52.98 | 322.00 |
|
Cash Flow from Investing Activities
|
-- | -1,067.00 | -159.46 | -20.34 | -350.90 |
|
Cash from Financing Activities
|
15.31 | 14.00 | 144.84 | 30.07 | 54.70 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Curanex Pharmaceuticals Inc (CURX) | Lineage, Inc. (LINE) | Viamet Pharmaceuticals Corp (VMET) | MAKO Surgical Corp (MAKO) | Republic Airways Holdings Inc (RJET) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-70.02 | -0.60 | 6.94 | 29.00 | 3.17 |
|
ROE (%)
|
-130.80 | -1.85 | 11.69 | 30.61 | 3.61 |
|
ROA (%)
|
-195.12 | -0.82 | 6.71 | 17.02 | 2.40 |
|
EBIT Margin (%)
|
-- | 7.97 | 71.08 | 41.30 | 9.67 |
|
Net Margin (%)
|
-- | -3.15 | 50.13 | 25.13 | 2.96 |
|
Cash Profit Margin (%)
|
-- | 0.00 | 0.00 | 0.00 | -- |
Growth Ratios
| Curanex Pharmaceuticals Inc (CURX) | Lineage, Inc. (LINE) | Viamet Pharmaceuticals Corp (VMET) | MAKO Surgical Corp (MAKO) | Republic Airways Holdings Inc (RJET) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-- | 1.03 | 1.89 | 0.61 | 134.15 |
|
EBIT Growth (%)
|
-3,634.70 | 216.94 | -- | -- | 200.33 |
|
Net Profit Growth (%)
|
-2,306.33 | 69.93 | 930.56 | 76.17 | 155.09 |
|
EPS Growth (%)
|
-2,255.51 | 71.97 | 22.18 | 0.56 | 88.62 |
|
Book Value Growth (%)
|
1,433.59 | -8.21 | -38.33 | 77.13 | 302.10 |
Valuation Ratios
| Curanex Pharmaceuticals Inc (CURX) | Lineage, Inc. (LINE) | Viamet Pharmaceuticals Corp (VMET) | MAKO Surgical Corp (MAKO) | Republic Airways Holdings Inc (RJET) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-0.11 | -81.43 | -- | 15.37 | 10.27 |
|
Price / Book Value
|
0.04 | 0.97 | -- | 3.44 | 0.59 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
0.99 | 15.81 | -- | 6.90 | 5.70 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Curanex Pharmaceuticals Inc (CURX) | Lineage, Inc. (LINE) | Viamet Pharmaceuticals Corp (VMET) | MAKO Surgical Corp (MAKO) | Republic Airways Holdings Inc (RJET) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | 0.79 | 0.00 | 0.00 | 0.63 |
|
Short term debt to equity ratio
|
0.02 | 0.00 | 0.13 | 0.07 | 0.15 |
|
Current Ratio
|
45.95 | 0.78 | 0.71 | 3.11 | 1.03 |
|
Quick Ratio
|
45.95 | 0.70 | 0.71 | 2.35 | 0.84 |
|
Interest Coverage
|
-493.63 | 0.70 | 4.83 | 109.90 | 2.65 |
Operating Efficiency Ratios
| Curanex Pharmaceuticals Inc (CURX) | Lineage, Inc. (LINE) | Viamet Pharmaceuticals Corp (VMET) | MAKO Surgical Corp (MAKO) | Republic Airways Holdings Inc (RJET) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
-- | 17.13 | 14.16 | 0.55 | 4.14 |
|
Asset Turnover
|
0.00 | 0.26 | 0.13 | 0.68 | 0.81 |
|
Receivable days
|
-- | 58.73 | 52.53 | 2.99 | 17.21 |
|
Inventory Days
|
-- | 13.39 | -- | 100.11 | 22.86 |
|
Payable days
|
-- | 93.39 | 35.28 | 59.08 | 27.62 |
|
Cash Conversion Cycle
|
-- | -21.28 | -- | 44.01 | 12.44 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
